

PATENT #9

**CONTINUED PROSECUTION APPLICATION (CPA)
REQUEST TRANSMITTAL**

R. Harman
2/18/04

COMMISSIONER FOR PATENTS
BOX CPA
Washington, D.C. 20231

Aventis Docket No.: **MO1660J US**
First-Named Inventor: **Sai P. Sunkara**
Examiner: **J. Goldberg**
Group Art Unit: **1614**

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail in an envelope addressed to Asst. Commissioner for Patents, Box DAC, P.O. Box 2327, Arlington, VA 22202, on

November 21, 2001
Date of Deposit

Sally Kapadia
Signature

EV 047246390 US
Express Mail No.

This is a request for a

- ☒ Continuation
☐ Divisional

application under 37 CFR 1.53(d) (continued prosecution application (CPA)) of:

Prior application number **09/160,977**, filed **September 25, 1998**.

Title: **METHOD OF TREATING CANCER BY CONJUNCTIVE THERAPY WITH 2'-HALOMETHYLIDENE DERIVATIVES AND A S-PHASE OR M-PHASE SPECIFIC ANTINEOPLASTIC AGENT**

☐ Enter the unentered amendment previously filed on _____ under 37 CFR 1.116 in the prior nonprovisional application.

☐ A preliminary amendment is enclosed.

☐ This application is filed by fewer than all the inventors named in the prior application, 37 CFR 1.53(d)(4).

☐ DELETE the following inventor(s) named in the prior nonprovisional application:

11/23/2001 SLUANG1 00000022 181982 09160977

02 FC:131

740.00 FH

☐ This application should be associated with Customer No. **005487**.

☐ Information Disclosure Statement (IDS) is enclosed:

- a. ☐ PTO-1449
b. ☐ Copies of IDS Citations


RECEIVED

NOV 26 2001

OFFICE OF PETITIONS

CLAIMS					
(1) FOR	(2) NUMBER FILED	(3) NUMBER EXTRA	(4) RATE	(5) BASIC FEE (\$740.00)	
TOTAL CLAIMS	12	- 20	x \$18.00	0.00	
INDEPENDENT CLAIMS	1	- 3	x \$84.00	0.00	
MULTI-DEPENDENT CLAIMS(S), Per Application (\$280.00)					
			TOTAL FILING FEE	\$740	

- ☒ Please charge my Deposit Account No. **18-1982** in the amount of \$740.
A duplicate copy of this sheet is enclosed.
- ☒ The Commissioner is hereby authorized to charge any fees under 37 C.F.R. 1.16 and 1.17 which may be required by this paper, for credit any overpayment to Account No. **18-1982**.
A duplicate copy of this sheet is enclosed.



Mark C. Nelligan, Reg. No. 36,389
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Mail Code: EMC-G1
Bridgewater, New Jersey 08807-0800
Telephone (908) 231-**2388**
Telefax (908) 231-2626

Docket No. MO1660J US
November 21, 2001